Lupus Erythematosus, Systemic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This case control study was performed to investigate interrelationship between high sensitivity C-reactive proteins (hs-CRP), Interleukin-6 (IL-6) levels and disease activity among SLE patients.
|
27531690 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Compared with HCs (n=30), patients with SLE (n=36) scored higher on measures of depression, fatigue and had higher hsCRP (p=0.013), IL-6 (p=0.003) and B lymphocyte stimulator (p<0.001).
|
30979715 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thus, increased Th17/Th1 and Th17/Treg ratios were found in SLE patients but not in pAPS patients. pAPS and SLE patients had higher serum IL-6 levels than HC but there was not difference between both disease groups.
|
30894863 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In addition, the frequency of IL-6-producing transitional B cells was positively correlated with disease activity in SLE patients, and these cells were significantly reduced after short-term standard therapies.
|
29563616 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> Plasma IL-1β levels were unmodified in SLE respect to HC whereas IL-6 levels were higher in SLE than in HC, resulting significantly increased in SLE-S. Macrophages isolated from SLE patients released lower quantities of IL-1β after stimulation with BzATP, whereas IL-6 release was significantly augmented in SLE-NS respect to both HC and SLE-S after all types of stimulation.
|
31110478 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that high expression of Fas, FasL and IL-6 and low expression of CTLA-4 by the CD8<sup>+</sup>CD28<sup>+</sup> T-cell subset promotes the activation-induced cell death of the CD8<sup>+</sup>CD28<sup>+</sup> T-cell subset, resulting in an imbalance of CD8<sup>+</sup>CD28<sup>-</sup>/CD8<sup>+</sup>CD28<sup>+</sup> T cells in active SLE patients, which represents an important feature in the immunological pathogenesis of SLE.
|
31399013 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A higher TGF-β and IL-6 serum level were found in SLE patients compared to controls (both p<0.0001).
|
30943147 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-18 predicts the risk of active renal SLE while IL-6 and IL-8 predict the risk of active non-renal.
|
31842967 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Signaling Lymphocytic Activation Molecule Family Member 1 Engagement Inhibits T Cell-B Cell Interaction and Diminishes Interleukin-6 Production and Plasmablast Differentiation in Systemic Lupus Erythematosus.
|
30058241 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
PC1 changes from controls to SLE-HDA patients, included: the increased impact of IL-1β (from 0.58 to >0.95); increased impact of IL-6 in HDA (0.76); increased influence of MIP-1α (0.60) and MIP-1β (0.85); and the uncoupling of TGF-β1 (0.14).
|
30551949 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-6 and IL-17A concentrations were significantly higher in SLE/CP patients than controls/CP.
|
30148445 |
2019 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
The expressions of vascular cellular adhesion molecule-1 (VCAM-1), intracellular adhesion molecule-1 (ICAM-1), interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1) in MRL/lpr mouse glomerular endothelial cells (lupus-MGECs) were estimated by quantitative real-time polymerase chain reaction, enzyme-linked immunosorbent assay and Western blotting.
|
30268079 |
2018 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
OI pretreatment inhibited mRNA expression and the production of multiple pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) in SLE patient-derived PBMCs and lipopolysaccharide (LPS)-activated THP-1 cells.
|
30466076 |
2018 |
Lupus Erythematosus, Systemic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A positive correlation was found between serum BAFF and IL-6 levels in patients with SLE but not in pAPS (p = 0.011).
|
29462939 |
2018 |
Lupus Erythematosus, Systemic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our results suggest that MIF can induce a differential inflammatory response in physiological and pathological conditions with a predominance of a Th17 cytokine profile in PBMC from HS and an increase in TNF-α and IL-6 expression in PBMC from active SLE patients.
|
29397904 |
2018 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
In a clinical trial for anti-IL-6 in patients with systemic lupus erythematosus, we measure interferon (IFN) status, anti-IL-6 drug exposure, and whole blood genome-wide gene expression at three time points.
|
30340504 |
2018 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-6, ESR and CIC significantly increased in active clinical SLE.
|
29422675 |
2018 |
Lupus Erythematosus, Systemic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated levels of serum IL-6 are well documented with the disease activity and anti-dsDNA antibodies in SLE.
|
28530463 |
2017 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we report the unexpected finding that a lack of B cell-derived IL-6 abrogates spontaneous GC formation in mouse SLE, resulting in loss of class-switched autoantibodies and protection from systemic autoimmunity.
|
28899868 |
2017 |
Lupus Erythematosus, Systemic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We examined whether serum levels of IL-6 and CRP are associated with upper and lower extremity muscle strength among adult women with SLE.
|
27863333 |
2017 |
Lupus Erythematosus, Systemic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This gene was capable of encoding a fully functional Env glycoprotein that was found to contain a domain, the immunosuppressive (ISU) domain, that, when evaluated ex vivo in patients with SLE and those with rheumatoid arthritis as well as in animal models, showed strong antiinflammatory activity, including the ability to lower IL-6 levels.
|
27696782 |
2017 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.
|
27672124 |
2017 |
Lupus Erythematosus, Systemic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IL-6, IL-12, IL-17, IFN-γ and IL-10 levels were significantly higher in SLE, while IL-4 was lower in SLE.
|
28649995 |
2017 |
Lupus Erythematosus, Systemic
|
0.400 |
Biomarker
|
disease |
BEFREE |
<i>Conclusion.</i> Both IL-1<i>β</i> and IL-6 are highly expressed cytokines in RF+IgE+ SLE subtype which may be related to the pathogenesis of this special SLE subtype and provide accurate treatment strategy by neutralizing IL-1<i>β</i> and IL-6.
|
28286780 |
2017 |
Lupus Erythematosus, Systemic
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Interferon-γ, interleukin-6, and interleukin-12 levels were significantly increased in plasma from patients with SLE with active nephritis (AN), as compared to both patients with SLE with inactive nephritis (IN) and the control group.
|
29208022 |
2017 |